Work

1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy

Year: 2023

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.2173

Authors: A.N. Starodub, S-B. Kim, D. Davar, J. Powderly, A.G. Hill, O. Yeku, N. Gabrail, C. Krapp, S. Pihl, M. Chen, S. Slavsky, D. Torrejon Castro, S.M. Singel, V. Kwatra

Institutions: Christ Hospital, Asan Medical Center, University of Ulsan, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Carolina BioOncology Institute, Harvard University, Massachusetts General Hospital, Gabrail Cancer Center, Ascendis Pharma (Denmark)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4387811270

FWCI: 0.244

Cites:

Cited by: 2

Related to: 10